Shameless promotion of colleagues. Rob O'Brien will be moderating a panel on the payer perspective around industry disruption. No shortage of topics on that front to bring up, that's for sure!
read full article ›News in recent months of strategic shifts or closures at #PDT leaders highlights how tough the prescription digital therapeutics business. One of the primary reasons things are tough? There isn't a straightforward path to reimbursement by payers. As such, the subcommittee hearing scheduled for Sept. 19 is a very important step forward for #PDT businesses. It's an even bigger step forward for patients who may benefit from these new digital modalities.
read full article ›The @Real Endpoints team had so much fun participating in the latest Insight Exchange with Alex Guth and Matthew Mancuso of L.E.K. to highlight learnings from our inaugural gene therapy commercial meeting. Tune in to hear Roger Longman and Ellen Licking opine (because, you know, that soooo rarely happens. 😉)
read full article ›As PBM reform heats up on Capital Hill, this story is sure to make waves. Not only are there juicy quotes about how intermediaries are making money at the expense of consumers, but it highlights the perverse incentives that have been created as insurers have bought up PBMs. As one industry watcher told us, "this is another nail the PBM coffin, but it's clearly going to take a long time for the coffin to be finished."
read full article ›Today's must-read story post the announcement of the first 10 drugs to face drug price negotiation is from the team at STAT. It is a reminder that when it comes to what to do about rising healthcare costs, hospitals and doctors aren't necessarily in favor of price caps either.
read full article ›Brian Reid lays out another essential daily dozen #IRA related news stories in today's newsletter. If you are interested in drug policy and reimbursement or how to communicate product value, do yourself a favor and subscribe to Cost Curve.
read full article ›Wall Street's muted response after HHS released the long await list of ten Part D drugs slated for price negotiation under the Inflation Reduction Act. While there were some surprises (e.g., Farxiga, Stelara, and Entresto), analysts clearly believe the news will NOT have that much financial impact on drugmakers. (Leerink called the announcement “immaterial” in a note to investors.)
read full article ›Our co-founder and chairman has some thoughts on recent moves by CVS Health.
read full article ›One week after Blue Shield of CA's announced it was dropping CVS CareMark as its overall PBM and contracting with new vendors such as Amazon and Mark Cuban Cost Plus Drug Company, PBC, comes this: CVS Health is forming a new subsidiary Cordavis to work with drugmakers to produce and commercialize biosimilars. The first partnership on the docket: a tie-up with Sandoz for its Humira #biosimilar #Hyrimoz
read full article ›For many #lifesciences companies, employers are a black box. These survey findings from Business Group on Health help elucidate some of the top priorities of a key #stakeholder in the healthcare #ecosystem.
read full article ›